Please assess the completion status of the following clinical trial:

Trial Title: TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 years or more.~2. Pathologically-verified diagnosis of colorectal adenocarcinoma.~3. Measurable metastasis to liver with at least one dimension ≥ 1.0 cm.~4. Liver dominant metastases as judged by multidisciplinary team consensus review of cross-sectional imaging of the chest, abdomen and pelvis.~5. At least 2 weeks must have elapsed from the last dose of chemotherapy before starting HCQ and at least 4 weeks must have elapsed from the last dose of VEGF/VEGFR therapy prior to starting axitinib.~6. Subjects must be at least 2 weeks beyond prior radiotherapy or surgery, and have recovered from all therapy associated toxicities.~7. Eastern Cooperative Oncology Group (ECOG) Performance status must be 0-1 (see Appendix II).~8. Absolute granulocyte count \> 1,500/ul, platelet count \> 75,000/ul, International Normalized Ratio (INR) \< 1.6~9. Serum creatinine \< 2.0 mg/dl; serum bilirubin \< 2.0 mg/dl.~10. Urine protein:creatinine ratio \< 1 or 24-hour urine protein \< 1 gm/day~11. Liver function Child-Pugh A~12. Competent and willing to provide informed consent~13. Patients of reproductive potential agree to use approved contraceptive methods per section 5.4~Exclusion Criteria:~1. Contraindications to angiography and selective visceral catheterization:~   1. severe allergy or intolerance to contrast media not controllable with prophylaxis.~  2. bleeding diathesis not correctable by usual forms of therapy.~  3. severe peripheral vascular disease precluding catheterization.~2. Contraindications to hepatic artery embolization:~   1. high risk of hepatic failure, indicated by the constellation of greater than 50% liver replacement by tumor, lactate dehydrogenase (LDH) \>425 mU/ml, aspartate aminotransferase (AST) \>100mU/ml. and bilirubin \>2 mg/dl.~  2. tumor volume \>75% of total liver volume.~  3. portal vein occlusion without hepatopetal collateral flow demonstrated by angiography; or portal hypertension with hepatofugal flow.~  4. hepatic encephalopathy.~3. Prior hepatic arterial infusion chemotherapy or hepatic radiation therapy. Prior surgical resection or ablation of liver metastases is acceptable.~4. No more than two prior lines of systemic chemotherapy.~5. Pregnancy or lactation~6. Known allergic reactions to irinotecan, HCQ or axitinib~7. Allergy to contrast not mitigated by usual prophylaxis~8. Serious infection requiring intravenous therapy.~9. Known retinal disease~10. Poorly controlled hypertension, defined as a blood pressure \> 150/100 at the time of enrollment. Patients with a preexisting hypertension must be on a stable anti-hypertensive regimen~11. History of abdominal fistula, gastrointestinal perforation, or serious non-healing wounds, ulcers, or bone fractures~12. Known New York Heart Association class II or greater congestive heart failure (defined as symptoms of fatigue, dyspnea, or other symptoms with ordinary physical activity)~13. Known untreated brain metastases. History of treated metastases off steroids allowed.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TACE+axitinib+HCQ (Type: EXPERIMENTAL): 2 weeks of axitinib 5mg BID and hydroxychloroquine 600 mg BID followed by lobar or segmental trans arterial chemoembolization monthly until the entire tumor burden is treated, then continue axitinib/HCQ until progression or intolerable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).